ASX Announcement 16 November 2026 Avecho presents at BIO-Europe – Europe’s largest biopharmaceutical partnering event Key Highlights • CEO Dr Paul Gavin presented Avecho at BIO-Europe 2026 in Cologne, Germany (9–11 November 2026), one of the largest international biopharmaceutical...
Avecho presents at BIO-Europe
Filed with ASX · · 17 pages · English
Summary by 6ix AI
Avecho Biotechnology Limited presented at BIO-Europe, a major biopharmaceutical partnering event, highlighting its pivotal Phase III trial for a cannabidiol product aimed at treating insomnia. CEO Dr. Paul Gavin emphasized the productive nature of the event, noting the engagement level with both existing and new parties. Avecho aims to license its product in territories outside Australia as it progresses through the final cohort of its trial.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Avecho Biotechnology Limited on 6ix
In the deck
Earlier from Avecho Biotechnology
- September 2026 Quarterly Activities Report & Appendix 4C
- Change of Chief Financial Officer
- Response to ASX Price Query
- Avecho to present at the Canaccord Drug and Device Confe
- Avecho to present at the ASX SMIDcaps Conference
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology